NCT04014101 (SHR-1210) is a Phase 2 clinical trial of SHR-1210 in Hepatocellular Carcinoma, sponsored by Shanghai Zhongshan Hospital.

Who is sponsoring NCT04014101?

NCT04014101 is sponsored by Shanghai Zhongshan Hospital.

What drugs are being tested in NCT04014101?

Interventions in NCT04014101: SHR-1210, apatinib.

What condition does NCT04014101 study?

NCT04014101 studies Hepatocellular Carcinoma.

Is NCT04014101 still recruiting?

NCT04014101 is currently status unknown. Last updated 11 July 2019.

Last reviewed 2019-07-11 · How we verify

NCT04014101: SHR-1210

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

SHR-1210 Plus Apatinib in Patients With Advanced-Stage Hepatocellular Carcinoma

Status unknown Phase 2 Last updated 11 July 2019

What this trial tests

Phase 2 trial testing SHR-1210 in Hepatocellular Carcinoma in 40 participants. Status unknown.

Timeline

1 June 2019

Primary endpoint
1 October 2019

1 October 2020

Quick facts

Lead sponsor	Shanghai Zhongshan Hospital
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	40
Start date	1 June 2019
Primary completion	1 October 2019
Estimated completion	1 October 2020
Sites	1 location across China

Drugs / interventions tested

SHR-1210 — full drug profile →
apatinib (Apatinib) — full drug profile →

Conditions studied

Hepatocellular Carcinoma — all drugs for Hepatocellular Carcinoma →

Sponsor

Shanghai Zhongshan Hospital

Who can join

Adults 18 to 100, any sex, with Hepatocellular Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

SHR-1210 is a humanized anti-PD-1 Immunoglobulin G4 (IgG4) monoclonal antibody. This is an open- label#single center #non-randomized #Single Arm Exploratory Study . This clinical study is an investigator-initiated clinical trial(IIT) .The objective of this study is to evaluate the efficacy and safety of therapy with anti-PD-1 antibody SHR-1210 and apatinib in patients with advanced stage hepatocellular carcinoma.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Immunotherapy for Hepatocellular Carcinoma: Current Status and Future Prospects.
Liu Z, Liu X, Liang J, Liu Y, et al · · 2021 · cited 109× · PMID 34675942 · DOI 10.3389/fimmu.2021.765101
Liver Cancer Immunity.
Ilyas SI, Wang J, El-Khoueiry AB. · · 2021 · cited 81× · PMID 32516437 · DOI 10.1002/hep.31416
Glucose Metabolism and Oxidative Stress in Hepatocellular Carcinoma: Role and Possible Implications in Novel Therapeutic Strategies.
Mossenta M, Busato D, Dal Bo M, Toffoli G. · · 2020 · cited 60× · PMID 32585931 · DOI 10.3390/cancers12061668
Resistance to PD-L1/PD-1 Blockade Immunotherapy. A Tumor-Intrinsic or Tumor-Extrinsic Phenomenon?
Chocarro de Erauso L, Zuazo M, Arasanz H, Bocanegra A, et al · · 2020 · cited 58× · PMID 32317979 · DOI 10.3389/fphar.2020.00441
Advances of Targeted Therapy for Hepatocellular Carcinoma.
Niu M, Yi M, Li N, Wu K, et al · · 2021 · cited 39× · PMID 34381735 · DOI 10.3389/fonc.2021.719896
Mechanisms and Clinical Trials of Hepatocellular Carcinoma Immunotherapy.
Huang SL, Wang YM, Wang QY, Feng GG, et al · · 2021 · cited 24× · PMID 34306031 · DOI 10.3389/fgene.2021.691391
Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: An Overview.
van Doorn DJ, Takkenberg RB, Klümpen HJ. · · 2020 · cited 18× · PMID 33374927 · DOI 10.3390/ph14010003
Combination of molecularly targeted therapies and immune checkpoint inhibitors in the new era of unresectable hepatocellular carcinoma treatment.
Liu ZL, Liu JH, Staiculescu D, Chen J. · · 2021 · cited 17× · PMID 34104226 · DOI 10.1177/17588359211018026

Verify or expand the search:

Other trials of SHR-1210

Trials testing the same drug.

NCT05799183 — A SHR-1210 BE Study on Healthy Subjects · Phase 1 · terminated
NCT04533490 — A Phase Ⅱ Clinical Trial of Camrelizumab for Adjuvant Treatment of Resectable Esophageal Squamous Cell Carcinoma · Phase 2 · unknown
NCT04680988 — A Study of SHR-1210± SHR-1020 Versus Chemotherapy in Patients With Recurrent or Metastatic Cervical Cancer · Phase 2 · completed
NCT04790539 — a Study of SHR1210 in Combination With Paclitaxel-albumin and Carboplatin in Extensive Stage Small Cell Lung Cancer · Phase 2 · unknown
NCT04506242 — Camrelizumab With Apatinib as Neoadjuvant Therapy for Participants With Resectable Non-Small Cell Lung Cancer · Phase 2 · unknown

Other recruiting trials for Hepatocellular Carcinoma

Currently open trials in the same condition.

NCT06902246 — Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma · Phase 2 · recruiting
NCT05842174 — Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma · Phase 1, PHASE2 · recruiting
NCT07417397 — Adjuvant TACE in HCC With High-risk Recurrence Factors · Phase 3 · recruiting
NCT07317414 — β-alanine in the Treatment of Advanced Hepatocellular Carcinoma · Phase 2 · recruiting
NCT07148050 — Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimer · Phase 1 · recruiting

Other Shanghai Zhongshan Hospital trials

Trials by the same sponsor.

NCT07353476 — Radiotherapy Plus Anti-PD-1 Versus Anti-PD-1 Alone in ypTanyN⁺M0 NSCLC · Phase 2 · not yet recruiting
NCT07508956 — Feasibility of Circulating Tumor DNA Based Minimal Residual Disease-Guided Adjuvant Therapy in Locally Advanced Gastric · Phase 3 · not yet recruiting
NCT07535632 — SBRT Followed by PD-1 Inhibitor, Bevacizumab and TAS-102 as Third-Line Therapy for Recurrent/Metastatic Colorectal Cance · Phase 2 · not yet recruiting
NCT07531368 — BBAP With CS Mapping Guidance · NA · not yet recruiting
NCT07501104 — Neoadjuvant Pucotenlimab Combined With Lenvatinib and Temozolomide in Resectable Stage IIB/III Acral Melanoma · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04014101 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shanghai Zhongshan Hospital
Last refreshed: 11 July 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04014101.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing